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ABSTRACT 
Drug discovery is a continuous process where researchers are constantly trying to find new 
and better drugs for the treatment of various conditions. Alzheimer’s disease, a 
neurodegenerative disease mostly affecting the elderly, has a complex etiology with several 
possible drug targets. Some of these targets have been known for years while other new 
targets and theories have emerged more recently. Cholinesterase inhibitors are the major 
class of drugs currently used for the symptomatic treatment of Alzheimer’s disease. In the 
Alzheimer’s disease brain there is a deficit of acetylcholine and an impairment in signal 
transmission. Acetylcholinesterase has therefore been the main target as this is the main 
enzyme hydrolysing acetylcholine and ending neurotransmission. It is believed that by 
inhibiting acetylcholinesterase the cholinergic signalling can be enhanced and the cognitive 
symptoms that arise in Alzheimer’s disease can be improved.  
 
Butyrylcholinesterase, the second enzyme of the cholinesterase family, has more recently 
attracted interest among researchers. Its function is still not fully known, but it is believed to 
play a role in several diseases, one of them being Alzheimer’s disease. In this contribution 
the aim has primarily been to identify butyrylcholinesterase inhibitors to be used as drug 
molecules or molecular probes in the future. Both synthetic and natural compounds in 
diverse and targeted screening libraries have been used for this purpose. The active 
compounds have been further characterized regarding their potencies, cytotoxicity, and 
furthermore, in two of the publications, the inhibitors ability to also inhibit Aβ aggregation in 
an attempt to discover bifunctional compounds. 
 
Further, in silico methods were used to evaluate the binding position of the active 
compounds with the enzyme targets. Mostly to differentiate between the selectivity towards 
acetylcholinesterase and butyrylcholinesterase, but also to assess the structural features 
required for enzyme inhibition. We also evaluated the compounds, active and non-active, in 
chemical space using the web-based tool ChemGPS-NP to try and determine the relevant 
chemical space occupied by cholinesterase inhibitors. 
 
In this study, we have succeeded in finding potent butyrylcholinesterase inhibitors with a 
diverse set of structures, nine chemical classes in total. In addition, some of the compounds 
are bifunctional as they also inhibit Aβ aggregation. The data gathered from all publications 
regarding the chemical space occupied by butyrylcholinesterase inhibitors we believe will 
give an insight into the chemically active space occupied by this type of inhibitors and will 
hopefully facilitate future screening and result in an even deeper knowledge of 
butyrylcholinesterase inhibitors. 
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1 REVIEW OF THE LITERATURE 
1.1 Cholinesterases 
Cholinesterases belong to the enzyme family of serine hydrolases, the name comes from 
their ability to hydrolyse substrates using an active site nucleophilic serine residue. The 
serine hydrolase superfamily is a large group of proteins involved in many important 
physiological processes e.g. digestion (Whitcomb and Lowe, 2007), blood coagulation 
(Flemmig and Melzig, 2012) and neurotransmission (Pohanka, 2011), and therefore many of 
these enzymes have also been linked to various diseases such as pancreatitis, thrombosis, and 
Alzheimer’s disease (AD). Thus they serve as valid targets for drug discovery and in fact 
many inhibitors of these enzymes have been developed into drugs that are in clinical use 
today, for example Exelon® (Novartis) and Aricept® (Eisai) for AD, Pradaxa® (Boehringer 
Ingelheim) and Xarelto® (Bayer) for thrombosis and Januvia® (Merck) and Onglyza® 
(Bristol-Myers Squibb) for type 2 diabetes (Bachovchin and Cravatt, 2012). However, there 
are still many of the serine hydrolases that need to be characterized as their function and 
substrate specificity is still not known. The cholinesterases consist of acetylcholinesterase 
(AChE) and butyrylcholinesterase (BChE), both of these have known structures but only the 
first one has a well-established function. In the next sections the profile of these two 
enzymes will be discussed. 
 
1.1.1 Acetylcholinesterase 
Acetylcholinesterase (AChE, EC 3.1.1.7), also known as e.g. cholinesterase, acetylcholine 
acetylhydrolase, true cholinesterase and choline esterase I, is considered the main enzyme in 
the cholinesterase family. In humans, AChE is encoded by a single gene, ACHE, that is 
located on the long arm of chromosome 7 at position 7q22 (Getman et al., 1992). Different 
molecular forms of AChE are produced by alternative mRNA splicing and post-translational 
associations of catalytic and structural subunits, which gives AChE its structural diversity. 
The hydrophilic species can form disulfide-linked dimers and tetramers and they are the 
main form of AChE. Additionally, AChE can be attached to the cell membrane using 
glycophospholipid anchors or collagen links (Taylor and Radić, 1994; Massoulié et al., 
1999). AChE is found in most tissues, but most notably in neuromuscular junctions (Guerra 
et al., 2005), brain cholinergic synapses (Adler et al., 2011), autonomic ganglia (Vernino et 
al., 2008) and red blood cell membranes (Delaunay, 1977). 
 
Crystallization of AChE has identified the residues encompassing the substrate binding 
pocket as well as the catalytic triad responsible for the hydrolase activity. The structure of 
AChE has been extensively investigated and almost 50 % of the structures published in the 
Protein Data Bank (PDB) (http://www.rcsb.org/pdb/home/home.do) to date have been 
prepared using the electric ray (Torpedo californica) enzyme, 36 % using mouse enzyme and 
only 8 % using the human AChE. The first crystal structure of AChE was solved in 1991 
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using Torpedo californica (Harel et al., 1993) while the first structure of human AChE 
appeared in 2000 (Kryger et al., 2000) (Figure 1). In addition, the human AChE in complex 
with therapeutic drugs aiming to inhibit AChE has recently been solved (Cheung et al., 
2012).  
 
 
Figure 1. The first crystal structure of human AChE (PDB ID: 1B41 (Kryger et al., 2000) drawn with 
PyMOL (The PyMOL Molecular Graphics System, Schrödinger LCC, open source v.1.2x. 
http://www.pymol.org) and the origin of the available crystal structures of AChE in PDB (July 2013, 
keyword: 3.1.1.7). 
 
AChE is best known for its function as a modulator of neurotransmission by hydrolysing 
acetylcholine (Figure 2). Acetylcholine is synthesised by choline acetyltransferase and 
concentrated into synaptic vesicles where it is stored until released into the synaptic cleft 
(Gauthier, 2002). In the synaptic cleft acetylcholine stimulates presynaptic nicotinic and 
muscarinic type 2 receptors and postsynaptic muscarinic type 1 receptors. AChE is also 
involved in many other functions such as apoptosis (Zhang et al., 2002; Zhang and 
Greenberg, 2012), cellular differentiation and tumorigenesis (Small et al., 1996). The 
kinetics of AChE is among the fastest in nature (Massoulié et al., 1993) and it allows the 
rapid termination of the neural signal. AChE is sensitive to organophosphates, as they 
irreversibly inhibit AChE by forming a covalent bond with the active serine residue, which 
has made organophosphates usable as pesticides, and sadly enough in chemical warfare 
(Pohanka, 2011). A continuous receptor stimulation by acetylcholine results in symptoms 
such as convulsion, vomiting, confusion and respiratory failure (Eddleston et al., 2008). On 
the other hand, a lack of acetylcholine reduces receptor stimulation which can be seen for 
example as the cognitive impairment occurring in AD (Garcia-Alloza et al., 2005). Thus, 
keeping a balance of acetylcholine activity is essential. 
 
Figure 2. Reaction cascade of acetylcholinesterase hydrolysing acetylcholine. 
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1.1.2 Butyrylcholinesterase 
Butyrylcholinesterase (BChE, EC 3.1.1.8), also known as e.g. pseudocholinesterase, 
acylcholine acylhydrolase, non-specific cholinesterase and choline esterase II, is a 
glycoprotein of 340 kDa (Asojo et al., 2011) encoded by a gene, BCHE, that, in humans, is 
located on the long arm of chromosome 3 at position 3q26.1-q26.2 (Gaughan et al., 1991). 
As for AChE, BChE also exists in several molecular forms. BChE can form soluble 
monomers (G1), dimers (G2) and tetramers (G4) and also exists in a G4 membrane-bound 
form (Darvesh et al., 2003). In contrast to AChE, BChE is more active in the peripheral 
tissue than in the brain (Liston et al., 2004) and mostly found in serum and glial cells, but 
also present in neurons (Darvesh et al., 1998; Darvesh and Hopkins, 2003). The longer half-
life of BChE has been proposed to be due to its high amount of glycosylation (Nachon et al., 
2002). 
 
In contrast to AChE, the crystal structures of BChE that are currently available in PDB use 
the human enzyme. The first crystal structure of a human BChE was solved in 2003 (Nicolet 
et al., 2003) (Figure 3). However, it was lacking some of the amino acids and four years 
later the structure of the full-length human BChE was published (Ngamelue et al., 2007). 
Several other structures of human BChE have since then been published (e.g. Asojo et al., 
2011; Carletti et al., 2011; Carletti et al., 2013; Wandhammer et al., 2013). 
 
 
Figure 3. The first crystal structure of human BChE (PDB ID: 1POI (Nicolet et al., 2003) drawn with 
PyMOL (The PyMOL Molecular Graphics System, Schrödinger LCC, open source v.1.2x. 
http://www.pymol.org) and the origin of the available crystal structures of BChE in PDB (July 2013, 
keyword: 3.1.1.8). 
 
BChE has been implicated in various physiological processes, the most prominent being the 
hydrolysis of several choline and non-choline esters, such as acetylcholine (Mesulam et al., 
2002), succinylcholine (Kaufman et al., 2011), cocaine (Xue et al., 2011) and aspirin 
(Masson et al., 1998), thus, playing an important part in neurotransmission, anaesthesia and 
drug abuse. In contrast to AChE, which is sensitive to organophosphates, BChE is not 
affected by them and is in fact being studied for use as a detoxification enzyme, a 
bioscavenger, for organophosphates (Mumford and Troyer, 2011; Mumford et al., 2012; 
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Zhang et al., 2012a) so that they are destroyed (hydrolysed) before reaching their target in 
the central nervous system (CNS). However, the function of BChE is still being debated. 
 
1.1.3 Structural differences in the active site 
Although, AChE and BChE are encoded on different chromosomes they show 65 % amino 
acid sequence homology (Giacobini, 2004) and they both contain a catalytic triad that is 
comprised of the amino acids serine (Ser), histidine (His), and glutamic acid (Glu) which are 
located at the bottom of a 20 Å gorge (Nicolet et al., 2003; Dvir et al., 2010). The amino 
acids lining this gorge seem to determine the substrate selectivity as the entry to AChE is 
narrower than that of BChE, which is shown in Figure 4A and Figure 4B. This is mainly 
due to the aromatic residues Tyr-124 and Trp-286 which are located at the gorge entrance 
and which are occupied by Gln-119 and Ala-277 in BChE. Inside the gorge, there is a 
difference in the acyl binding site residues which in AChE consist of the aromatic residues 
Phe-295 and Phe-297, while BChE contains the smaller residues Leu-286 and Val-288 
(Nicolet et al., 2003; Dvir et al., 2010) (Figure 4C). This allows BChE to bind bulkier 
substrates into the active site. Tyr-337 (Ala-328 in BChE) in AChE also hinders bulkier 
substrates from interacting with the catalytic triad. 
 
A)    B)     C) 
 
Figure 4. The active site entrance of A) human AChE [PDB code 3LII (Dvir et al., 2010)] and B) 
human BChE [PDB code 2PM8 (Ngamelue et al., 2007)]. C) A comparison between the residues in the 
active sites is also shown (the catalytic triad is visualized in violet). Drawn with PyMOL (The PyMOL 
Molecular Graphics System, Schrödinger LCC, open source v.1.2x. http://www.pymol.org). 
 
1.2 Cholinesterases as targets in drug discovery 
Due to the role of cholinesterases in several key functions in the human body, it has been 
postulated that they play a crucial role in several diseases and thus they have become central 
targets in drug discovery. Inhibitors of cholinesterase have been used in the therapy of AD 
(Birks, 2006) and myasthenia gravis (Mehndiratta et al., 2011), and have been suggested to 
be beneficial in the management of several other conditions e.g. chronic pain (Folkesson et 
al., 2010; Wehrfritz et al., 2010) and type 2 diabetes (Kamal et al., 2009). The use of 
cholinesterase inhibitors is not a cure but a temporary aid, usually at the earlier stages of the 
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disease (Birks, 2006). Cholinesterase inhibitors have received much criticism, and even 
though they have been the first-line therapy for AD patients for 20 years, their efficacy is still 
being questioned (see e.g. Lanctôt et al., 2009; Rountree et al., 2013). Although they do not 
benefit all AD patients they still remain an important part of disease therapy improving the 
daily life of many of those receiving this medical treatment. The most significant disease 
benefiting from cholinesterase inhibition, AD, will be discussed in the next section. 
 
1.2.1 Dementia: Alzheimer’s disease 
Dementia is a condition that affects the function of the brain as nerve cells stop functioning 
properly and start deteriorating. Depending on the area of the brain that is affected, cells that 
manage functions such as memory, language, judgment and behaviour, fail (Aranda-Abreu et 
al., 2011), making it a difficult condition not only for the patients but also for the caregivers. 
The cause of dementia is usually an underlying neurological disorder, but it can also be 
caused by changes in the brain due to factors such as brain injuries or vitamin B12 deficiency 
(Moore et al., 2012; Sivanandam and Thakur, 2012). The types of dementia include vascular 
dementia, frontotemporal dementia, dementia with Lewy bodies and AD. Of these, AD is the 
most common form of dementia and estimated to affect over 35 million people worldwide 
(http://www.alz.co.uk/research/files/WorldAlzheimerReport-ExecutiveSummary.pdf). This 
number is growing rapidly as the population ages, and it has been predicted it will affect 1 in 
85 people by the year 2050 (Brookmeyer et al., 2007). This high incidence, together with the 
severity of the disorder has made it a major research area; however, no cure is yet available 
and life expectancy after the disease is diagnosed is 3-10 years (Zanetti et al., 2009). In fact, 
AD is one of the leading causes of death in the high-income countries (WHO fact sheet Nr 
310. The top 10 causes of death. World Health Organization, 2011). 
 
The gradual deterioration of the AD brain is seen as a worsening of the patient’s condition 
from not remembering names to not being able to dress themselves and ultimately needing 
full-time care. In a report published in 2012 by WHO and the Alzheimer’s Disease 
International (ADI), it was emphasized that dementia needs to be considered a public health 
priority (Dementia: A public health priority. World Health Organization and Alzheimer’s 
Disease International, 2012). The population is growing older and to be able to cope with this 
new burden awareness needs to be raised and treatment plans made. The slow progression of 
AD makes it a difficult condition to detect. The first signs include personality changes and 
problems with recent memory, but these, however are common signs that can appear as 
result of normal aging and do not necessarily mean a person has AD.  
 
Elderly people with memory problems may have a condition called mild cognitive 
impairment (MIC), a sort of middle stage between normal aging and dementia (Gauthier et 
al., 2006), which can often develop into AD. Generally, AD is divided into three stages; 
mild, moderate, and severe AD. Mild AD is considered when memory loss begins occurring, 
and the patient starts forgetting names and where things are. In addition, personality changes 
can be observed. When a patient develops moderate AD, memory becomes even more 
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impaired and, for example, recognizing familiar faces becomes problematic. At this stage 
daily activities such as getting dressed are difficult and more personality changes can be 
observed. The patient might even experience hallucinations, paranoia and start to become 
violent. At the severe AD stage the disease is so advanced that the patient is unaware of their 
surrounding and unable to talk, eat, and take care of themselves. There are several different 
scales to assess the cognitive impairment of AD patients, among them are the most widely 
used Mini-Mental State Examination and the Alzheimer’s Disease Assessment Scale – 
Cognitive subscale (Robert et al., 2010). These are continuously used in clinical trials to 
evaluate the effect of the treatment. 
 
The disease is said to first have been described by Dr Alois Alzheimer in 1906 as he 
presented a peculiar disease of the brain which formed plaques and tangles (Holtzman et al., 
2011). Considering that AD has been known for over 100 years, it is only in recent years that 
AD research has truly expanded with new drug targets emerging with new hope for AD 
pharmacotherapy. However, at the same time pharmaceutical companies that have invested 
in AD drug therapy and other CNS disorders are becoming more reluctant to continue to 
invest in these programs as they are considered to be risky with many drug candidates failing 
in clinical trials. The problem lies in the numerous physiological changes that occur in the 
AD brain that cannot be simplified into one single affected pathway. This complexity has 
become more apparent as the knowledge of this pathology progresses. There are many 
unanswered questions regarding the cause of AD and it is not an easy task to identify which 
is the original cause of the disease and which are consequences of the body’s response to the 
original physiological change. Over the years several theories have emerged, but there is still 
no definite answer. Some of the hypotheses will be discussed briefly in the following section. 
 
The cholinergic hypothesis and cholinesterases 
The cholinergic hypothesis is the oldest of the hypotheses and arose from the fact that there 
is a significant loss of cholinergic neurons in the brain of AD patients as well as a reduced 
activity of choline acetyltransferase which catalyzes the production of acetylcholine, 
resulting in decreased neurotransmission and cognitive dysfunction (Whitehouse et al., 1982; 
Francis et al., 1999; Gauthier, 2002). Also a reduction in nicotinic and muscarinic receptors 
has been observed (Francis et al., 2010). By using cholinesterase inhibitors the levels of 
acetylcholine, which have a central role in cognitive functions (Liston et al., 2004), can be 
restored. In research, AChE has usually been the main drug target but lately the research has 
also been focused on the search for BChE inhibitors (e.g. Darvesh et al., 2007; Decker et al., 
2008; Carolan et al., 2010; Nawaz et al., 2011). This is due partly to the fact that the activity 
of BChE seems to be unaffected by the changes occurring in the AD brain while the activity 
of AChE seems to decrease (Giacobini, 2004). Thus in the AD brain, BChE performs a more 
central role in cholinergic transmission and with already depleted acetylcholine levels (Greig 
et al., 2005), this is believed to cause further cognitive decline. Both enzymes are present in 
neuritic plaques and neurofibrillary tangles (Mesulam et al., 1987) and inhibition of AChE 
and BChE increase the amount of free acetylcholine that can interact with neuronal receptors 
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(Lane et al., 2006). The importance of selectively inhibiting BChE has further been shown 
using aged rats where BChE inhibition augmented acetylcholine levels, increased cognitive 
function and decreased amyloid deposits (Greig et al., 2005). Researchers have also found a 
link between a less active variant of BChE (Ala539Thr) and a lower tendency to develop AD 
(Podoly et al., 2009). This supports the value of inhibiting BChE and is also the basis for 
selecting BChE as a primary target for this thesis project. Current therapies (discussed in 
section 1.2.1.1) are mostly based on the cholinergic hypothesis.  
 
The amyloid hypothesis 
The next two major hypotheses involve the original hallmarks of the disease, amyloid 
plaques and neurofibrillary tangles, which have central roles in the pursuit of a next level 
strategy to combat AD (Karran et al., 2011; Duan et al., 2012). Amyloid plaques consist of 
amyloid beta (Aβ) peptides that cluster together and form extracellular aggregates impeding 
neuron function and causing neurotoxicity (Lorenzo and Yankner, 1994). The neurotoxic 
species of Aβ have been identified as the Aβ1-40/42 peptide species and are produced by 
proteolytic cleavage of the amyloid precursor protein (APP). APP is an integral membrane 
protein that is found throughout the body and is believed to regulate several processes such 
as synapse formation, neural plasticity (Turner et al., 2003), and dendritic spine formation 
and maintenance (Lee et al., 2010). APP can be processed in two ways, through the 
amyloidogenic pathway which produces Aβ by being cleaved by β- and γ-secretase or the 
non-amyloidogenic pathway where APP is cleaved by α- and γ-secretase producing the non-
toxic component α-sAPP. The increased level of Aβ in the AD brain has led to the amyloid 
cascade hypothesis (Hardy and Higgins, 1992), where researchers believe that targeting Aβ 
could reduce, or even stop, the progression of AD (Hardy and Selkoe, 2002; Karran et al., 
2011). In 1998, a study was made where oligomers instead of amyloid fibrils were found to 
be the neurotoxic species, resulting in the oligomer hypothesis (Lambert et al., 1998).  
 
Supporting the hypothesis are the recent findings that mutations in the APP gene have shown 
to be risk factors (e.g. at position 670, 671, 687, 692 and 693) (Cras et al., 1998; Kaden et al., 
2012) or protective (position 673) (Jonsson et al., 2012) against developing AD in certain 
populations. It seems that humans carrying the Ala673Thr mutation form less amyloidogenic 
peptides, this is probable because it is adjacent to the aspartyl protease β site in APP and thus 
reduces β cleavage (the amyloidogenic pathway). However, there are many researchers that 
oppose this hypothesis as it seems to be difficult to obtain data showing any substantial 
relationship between amyloid burden and cognitive decline in AD patients (Bishop and 
Robinson, 2002; Zhang et al., 2012b). Nevertheless, Aβ is still widely accepted as a potential 
target and therapy strategies include inhibition of Aβ aggregation (e.g. Stevens et al., 2013; 
Zhang et al., 2013), β-secretase (BACE) (e.g. Roberds et al., 2001; Efremov et al., 2012) and 
γ-secretase  (e.g. Meunier et al., 2013), and the stimulation of α-secretase (e.g. Marcade et 
al., 2008). It has also been shown that there is a connection between AChE and the formation 
of Aβ fibrils (Inestrosa et al., 1996) and that stimulation of muscarinic acetylcholine 
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receptors promotes the non-amyloidogenic pathway (Davis et al., 2010), thus linking the 
cholinergic and amyloid hypotheses.  
 
Tau hyperphosphorylation and emerging theories 
Tau stabilizes microtubules in the neurons, which are important for the cell structure as well 
as cellular trafficking (Gendron and Petrucelli, 2009). When tau becomes phosphorylated the 
dynamics of the microtubule becomes affected and thus also the cell functions it regulates. 
Increased kinase activity leads to persistent tau phosphorylation which leads to neurite 
retraction and synaptic dysfunction (Sayas et al., 2002; Sun et al., 2011) and in the long run 
to the appearance of insoluble tau neurofibrillary tangles (NFTs). Glycogen synthase kinase 
3 β (GSK3β) is a serine/threonine protein kinase that is involved in regulating cellular 
functions such as cytoskeletal organization, cell cycle regulation, and apoptosis (Hardt and 
Sadoshima, 2002). It co-localizes with dystrophic neurites, pre-tangles and NFTs 
(Boutajangout et al., 2011), and seems to have an important role in neuronal development 
(Kim and Snider, 2011). GSK3β inhibition decrease tau phosphorylation and thus 
microtubule stability in neurons remain intact (Hardt and Sadoshima, 2002). Inhibition of 
GSK3β has recently been proven to reduce memory deficit using a mice model (Ly et al., 
2013). 
 
The cholinergic deficit, amyloid burden and hyperphosphorylated tau are the most accepted 
disease theories. However, there are several other mechanisms that are believed to result in 
AD. Some researchers believe that the failure in metal transportation contributes to AD 
pathology as AβPP, presenilins and tau have been shown to participate in this transportation 
and the fact that metal perturbances in absence of AD pathology can lead to 
neurodegeneration and loss of cognition (Bush, 2013). Inflammation is thought to play a part 
in AD pathology as inflammatory constituents such as cytokines and cyclooxygenase-2 
(Rubio-Perez and Morillas-Ruiz, 2012) are present in the AD brain and the use of non-
steroidal anti-inflammatory drugs has been shown to reduces the risk of AD (in 't Veld et al., 
2001). However, it has not been proven to work as a treatment for patients already diagnosed 
with AD (Jaturapatporn et al., 2012). Mitochondrial dysfunction is also being investigated 
(Lunnon et al., 2012; Morán et al., 2012). Several recent reviews discuss these and other 
therapy approaches that are being considered for future successful AD treatment (see e.g. 
Hong-Qi et al., 2012; Huang and Mucke, 2012; Singh et al., 2012). 
 
1.2.1.1 Current therapies 
The treatment options for AD are cholinesterase inhibitors and an N-methyl-D-aspartate 
(NMDA) receptor antagonist (Farlow and Cummings, 2007; Farlow et al., 2008; van Marum, 
2008) (Figure 5). As AChE is the main enzyme to hydrolyse acetylcholine and thereby 
ending neurotransmission, AChE inhibitors were developed as a treatment strategy for AD. 
Tacrine, a non-competitive synthetic AChE inhibitor, which also inhibits BChE (Ibach and 
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Haen, 2004) was the first drug to enter the market and was approved by the U.S. Food and 
Drug Administration (FDA) in 1993 (Summers, 2006). At that time there were already 
discussions about the toxic effect of tacrine (Watkins et al., 1994) and nowadays tacrine is 
not commonly used due to tolerability and hepatotoxicity issues (Bachovchin and Cravatt, 
2012). However, the scaffold of tacrine has served as a starting point for medicinal chemists 
and many cholinesterase inhibitors taking advantage of the same ring structure as tacrine 
have been published (e.g. Chen et al., 2012; Hamulakova et al., 2012; Wang et al., 2012). 
The next generations of cholinesterase inhibitors included donepezil in 1996, rivastigmine in 
2000 and galanthamine in 2001 (van Marum, 2008), all of which have a greater affinity for 
AChE, although rivastigmine is considered a dual inhibitor as the difference in potency 
between AChE and BChE is minor (Giacobini, 2004). All the drugs were also authorized for 
the European market and are still used today for the symptomatic treatment of AD. 
Memantine is a low-affinity, uncompetitive inhibitor of NMDA receptors, which allows it to 
normalize glutamergic neurotransmission without hindering transmission completely 
(Parsons et al., 2007). Memantine was approved in Europe in 2002 and in the US one year 
later for patients with moderate-to-severe AD (Möbius, 2003; Hussar, 2004). The 
combinational therapy of cholinesterase inhibitors and memantine has also been extensively 
studied and has shown a positive outcome (Atri et al., 2013). 
 
    
 
 
    
 
 
Figure 5. Currently approved drugs in the US and Europe for the symptomatic treatment of AD. 
Galanthamine, rivastigmine and donepezil are cholinesterase inhibitors and memantine is an NMDA 
receptor antagonist. 
 
With regard to cholinesterase inhibitors, their benefits are often considered short-lived with 
no enduring effects. In several large controlled trials, cholinesterase inhibitors did not show 
significant effects in delaying or preventing conversion of patients from MCI to dementia 
(Petersen et al., 2005; Feldman et al., 2007; Winblad et al., 2008). The limitations of using 
cholinesterase inhibitors include several adverse effects (such as nausea, vomiting and 
diarrhoea) as well as the problem of accurately predicting which patients will respond to 
treatment. However, the failure of these studies could be explained by problems in trial 
Galanthamine Rivastigmine 
Donepezil Memantine 
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methods and analysis (Shanks et al., 2009) and the symptomatic effects of using 
cholinesterase inhibitors have been positively demonstrated in a number of other large, 
controlled trials. For example, a Cochrane review of 13 randomized, placebo-controlled, 
double blinded trials stated that galanthamine, donepezil and rivastigmine improve cognitive 
functions of patients with mild to moderate AD which could also be seen in measures of 
daily living and behaviour (Birks, 2006). The positive effects of cholinesterase inhibitors are 
regarded significant enough in order to use these drugs as a first-line therapy for mild to 
moderate AD, even though it is several decades since their discovery. However, considering 
the impact AD has on the patient as well as the caretakers and society, a better solution than 
symptomatic relief is sought. Ideally, the beneficial effect of an AD drug should be reflected 
in cognitive or behavioural improvements that would take place even after the treatment is 
stopped or interrupted. This would require a drug that modifies pathological steps leading to 
AD (disease-modifying drugs) and could be achieved by combining several targets, as has 
been done previously for example with the cholinesterases and Aβ aggregation. This is also 
something we have striven towards during this thesis work.  
 
1.2.1.2 Importance of biomarkers for AD 
As the therapeutic strategy for AD is likely to change in the near future, one important factor 
in upcoming drug development would be a more careful selection of patients during clinical 
trials. This could be achieved by using biomarkers that could aid in the process. The word 
biomarker, a biological marker, is used to define substances that can identify biological 
processes or disease states in an organism. Biomarkers are valuable for disease diagnosis and 
the requirement of a biomarker is that it should be reliable and stable enough to allow an 
early and accurate diagnosis. Biomarkers are also important for selecting drug candidates as 
they can aid in evaluating whether this candidate affects the underlying pathophysiology of 
the disease in question (Blennow, 2010). In order to combat AD in the most effective way, 
treatment needs to be started at an earlier stage before the disease has caused too much 
irreversible damage. The difficulty with AD is that the diagnostic criterion is too unspecific 
and drugs that are tested in clinical trials often seem to lack efficiency, which may be due to 
the fact that trial durations are too short and they are typically performed on advanced AD 
cases (Hampel, 2012). The search and validation of biomarkers that can help identify pre-
dementia and even pre-clinical asymptomatic stages of AD, is a very current and important 
field. Cerebrospinal fluid biomarker candidates reflecting AD pathology are total tau, 
phosphorylated tau and the 42 amino acid form of Aβ (Blennow, 2010). However, patients 
can have different burdens of Aβ, phosphorylated tau, inflammation and other factors 
involved in AD. Reliable biomarkers for AD can be used for predicting the transition from 
MCI to dementia (Parnetti et al., 2012) as well as future cognitive decline in healthy 
individuals (Bendlin et al., 2012; Paternicò et al., 2012). Neuroimaging is being used as a 
non-invasive way of monitoring the physiological changes occurring in the diseased brain 
(Reiman and Jagust, 2012) and by using radiotracers it is possible to measure the Aβ load in 
the brain as well as observe the changes in Aβ over time (Villemagne and Rowe, 2013). This 
enables monitoring of patients selected for clinical trials, make deeper assessments of trial 
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outcome and, further on, it could be used to identify patients that will benefit from specific 
drug treatments. Several drugs in clinical trials are thought to have failed due to patient 
selection and the identification of valuable biomarkers to assess the effect of the drug 
candidates is crucial (Blennow, 2010). 
 
1.3 The early drug discovery process 
Discovering and developing a new drug is a very long and costly process that usually takes 
between 10-15 years and costs an average of 1 billion dollars (Khanna, 2012). The greatest 
problem in the pharmaceutical industry is the high attrition rate. A majority of drug 
candidates fail in clinical trials, or even before, either due to adverse effects or the lack of 
efficiency (Khanna, 2012; Mullard, 2012). An important part of the drug discovery process is 
a good understanding of the disease in question so that a good drug target can be chosen. A 
drug target can be considered a gene or a gene product which is involved in the manifestation 
of a disease in an organism. When a drug target has been identified researchers initiate the 
search for drug candidates. This is usually done by screening sets of compounds (discussed 
in the next section) which are then narrowed down (Figure 6) by criteria such as activity, 
cytotoxicity and absorption, distribution, metabolism and excretion (ADME) properties. 
 
 
Figure 6. The compound attrition during the early drug discovery process. Of all the compounds tested 
during primary screening only a small number of compounds eventually continue along the drug 
discovery path and ultimately become drug candidates. Active compounds are generally considered 
those compounds that show desirable activity in the primary screening while hits are the active 
compounds from the primary screening where the activity has been confirmed and potencies 
determined. Further, leads are compounds that have been optimized from the hit compounds in order to 
improve the potency, selectivity, and in vitro ADME profile of the hit. 
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1.3.1 Screening approach 
Screening, in the early drug discovery process, implies searching for a certain activity among 
a selected set of compounds. The goal of screening diverse compound libraries is to identify 
chemical scaffolds which can serve as interesting starting points for development into drug 
candidates. Before the first microplate (also termed microtitre or multiwell plates) arrived in 
the 1950s, compounds were tested in a cuvette or test-tube and the screening process was 
low-throughput, that is, few compounds could be tested at a time. The introduction of 
microplates allowed for faster screening of larger libraries with reduced costs as less time 
and reagents were needed. Nowadays, high-throughput screening (HTS) and Ultra HTS 
(UHTS) is applied in the pharmaceutical industry which allows for faster screening of a large 
amount of compounds where 96-, 384-, and 1536-well formats are the most commonly used 
(Mayr and Bojanic, 2009). In the pharmaceutical industry, workstations are often fully 
automated with robots handling the plates, from taking the plate containing the compounds 
out of the storage, picking the compounds to be tested, preparation of the screening plate and 
reading it. In an academic environment the workstations are seldom connected and the plate 
handling between workstations is manual. Automation is not only beneficial because it is 
faster and lightens the workload for the researchers, but it also reduces variations between 
plates and potential human errors. The most common way of screening compounds is in a 
one-well composition, that is one compound is tested in one well. It is also possible to pool 
compounds so as to test several compounds in the same well (5-20 compounds/well) in order 
to increase throughput and reduce costs. However, this may lead to problems such as higher 
false positive and negative hits, aggregation or interference (Kainkaryam and Woolf, 2009). 
As the assay selection has an impact on the screening results it is crucial to choose a good 
assay which is cost-effective, rapid, accurate, and precise. The assay performance should be 
monitored in order to validate the assay and ensure that high quality data can be obtained 
from the screening (Zhang et al., 1999). 
 
There have been discussions regarding how screening libraries should be composed. Some 
believe that random libraries, libraries containing a diversity of structures, are more 
beneficial as this is more likely to yield novel structure classes for lead optimization. On the 
other hand, focused or targeted libraries, as the name implies, contains a smaller subset of 
compounds of a certain chemical class that is believed to have an effect on the desired target. 
Both approaches have their benefits and drawbacks, but are consider to complement each 
other, and so both are commonly used (Valler and Green, 2000). Lipinski’s rule of five 
(Lipinski et al., 1997) is often used as a guideline when preparing compound libraries. 
Lipinski and co-workers stated that molecules that have a molecular weight over 500, more 
than 5 H-bond donors or 10 H-bond acceptors and a LogP over 5 are more likely to have a 
poor absorption and permeation, thus making poor drugs. However, there are several drugs 
that do not apply to these rules, for example many antibiotics belonging to the glycopeptide 
and aminoglycoside chemical classes have a higher molecular weight as well as higher 
lipophilicity (O’Shea and Moser, 2008). Natural products are also considered to be an 
exception to this rule, although they generally comply with having low LogP and H-bond 
donors (Ganesan, 2008). The storage condition of a compound library is important as well, as 
Review of the literature 
13 
this will ensure that the quality of the compounds remains intact. Dimethyl sulphoxide 
(DMSO) is the most common solvent to dissolve compounds aimed for storage in compound 
libraries, which are usually stored at temperatures between -20 and +4 °C (Di and Kerns, 
2006). 
 
1.3.2 The screening approach during this thesis 
The primary target during this work has been BChE and the secondary target has been 
AChE. As mentioned earlier in section 1.2.1 Dementia: Alzheimer’s disease (The cholinergic 
hypothesis), considering recent experimental data, it is believed that inhibiting BChE could 
be beneficial and in a way offers a new target to a known subject. Cholinesterase activity can 
be measured using Ellman’s reagent [5,5’-dithiobis (2-nitrobenzoic acid), DTNB] (Ellman et 
al., 1961), Fast Blue B salt [3,3'-dimethoxy-4,4'-biphenylbis(diazonium) zinc chloride] (van 
Asperen, 1962) or assays using fluorescent labelling (Guilbault and Kramer, 1965; Parvari et 
al., 1983; Gainullina et al., 2006). Ellman’s reagent, which has been used in this thesis, react 
with the product of cholinesterase hydrolysis and forms a coloured product (5-thio-2-
nitrobenzoate) that can be spectrophotometrically measured at 412 nm (Ellman et al., 1961) 
(a detailed description of the assay can be found in section 3.2.1 Ellman’s reaction). In 
Figure 7 the procedure using the 96-well layout is visualized in a simplified way. 
 
 
Figure 7. Screening procedure using Ellman’s reagent (DTNB). A) Test compounds are transferred 
from the compound library to the screening plate and a positive and negative control is included in 
order to assess assay performance. B) Assay reagents are added into the screening plate [substrate, 
DTNB and a buffer containing bovine serum albumin (BSA)] and background signal measured. C) 
Enzyme addition starts the hydrolysis of the substrate and the formation of a coloured anion occurs due 
to the reaction of the hydrolysis product with the DTNB. Depending on the degree of enzyme 
inhibition, differences in the absorbance is observed. Maximal and minimal signal is obtained from the 
column containing the negative control (control not inhibiting the enzyme). 
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Considering that both the target and the assay had previously been validated, it allowed this 
project to start directly with the biomolecular screening for cholinesterase inhibitors, with a 
focus on BChE. The origin of the libraries was both natural and synthetic and they were 
tested on the enzyme target by the biochemical assay using Ellman’s reagent (Figure 7). The 
screening was monitored using the statistical parameters: signal window coefficient (Z’ 
factor), signal-to-background (S/B) ratio (Zhang et al., 1999), signal-to-noise (S/N) ratio 
(Bollini et al., 2002), and coefficient of variation of the assay (CVA) (Iversen et al., 2006) 
(equations can be found in section 3.3.3 Statistical analysis). The Z’ factor has been widely 
applied in both the industry and academia (Sui and Wu, 2007) since its introduction in 1999, 
as S/B and S/N in themselves are considered insufficient to evaluate the screening quality 
(Zhang et al., 1999). Further, the potency and kinetic mechanisms of the active compounds 
were determined in order to verify the hits. Additionally, all libraries and active compounds 
were analysed in chemical space using ChemGPS-NP (discussed in more detail on the next 
page; ChemGPS-NP as a tool in drug discovery), to assess the chemically relevant space for 
BChE inhibitors. With the help of medicinal chemists, in publication I and II, tasks such as 
hit refinement and structure-activity relationship was addressed and even a pharmacophore 
model was proposed. Additional assays were also used in order to shed light onto possible 
dual-activity and safety of the active compounds, such as the thioflavin T assay which 
detects Aβ aggregation and cytotoxicity studies. All of these methods have made it possible 
for us to find the hit compounds that will be presented in this thesis. The screening approach 
during this thesis project is visualized in Figure 8. 
 
 
 
Figure 8. The screening approach during this thesis project. The full arrows indicate paths taken in all 
four publications while the dotted arrows represent approaches taken in different publications 
(indicated in the figure). In the case of publication II the entire library was tested for cytotoxicity. 
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ChemGPS-NP as a tool in drug discovery 
As previously mentioned, one tool that has been used during this thesis project is ChemGPS-
NP (Larsson et al., 2007; Rosén et al., 2009). ChemGPS-NP is an online navigation tool 
(http://chemgps.bmc.uu.se) that allows the user to navigate in chemical space so as to 
identify the chemical space that contains compounds with a desired activity. ChemGPS-NP 
is based on Principal Component Analysis (PCA) for a reference set of compounds and uses 
2D descriptors that describe physical-chemical properties, which means that stereochemistry 
and geometry of the molecules are not taken into account (as for 3D descriptors). Novel 
compounds are mapped into the chemical space via interpolation based on PCA score 
prediction. The principal component (PC) score is obtained by entering Simplified Molecular 
Input Line Entry Specification (SMILES) (Weininger, 1988), a string of characters and 
numbers translated from the molecules structure, into the model. The pathway of using 
ChemGPS-NP in this thesis project is described in Figure 9. 
 
 
 
Figure 9. Sequential visualization of how compounds are drawn in chemical space using ChemGPS-
NP. A-B) The canonical SMILES of the compounds, in this case the known cholinesterase inhibitors 
tacrine, physostigmine, rivastigmine, donepezil and galanthamine, are obtained by either drawing the 
structure or entering the name in the search engines of online webpages such as Molinspiration or 
ChemSpider. C) The SMILES that are provided using these search engines are D) entered on the 
ChemGPS-NP webpage which then E) calculates the PC scores (designated PS in the results obtained 
on the webpage). F) Using these PC scores the compounds are mapped into a 3D graph which allows 
for clearer visualization of the chemical space occupied by a compound library or certain compounds, 
for example hits. 
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It is a common practice nowadays in drug discovery to use a combination of in vitro and in 
silico methods to gather data on compounds. The information obtained from using 
ChemGPS-NP together with potency, molecular docking, and cytotoxicity studies gives a 
first profile of the active compounds. Thus, combining theses methods, we have sought to 
identify new and potent cholinesterase inhibitors in this thesis project. Although 
cholinesterase inhibitors are symptomatic treatment of AD, new and improved inhibitors are 
needed and using a combination of in vitro and in silico tools to evaluate compound 
characteristics is a good way forward. 
Aims of the study 
17 
2 AIMS OF THE STUDY 
The majority of the screening to find new cholinesterase inhibitors have been focused on 
AChE inhibitors. In this project, the focus has been on identifying new chemical classes of 
inhibitors that are either selective inhibitors of BChE or dual BChE/AChE inhibitors. 
 
The specific aims were as follows 
 
I. To identify BChE inhibitors from a collection of diverse synthetic compounds 
based on naturally present scaffolds using an in vitro assay and to further test 
their ability to inhibit Aβ aggregation, as this has an implication in AD. 
 
II. Phenothiazines have been shown to inhibit BChE. In this study we wanted to 
verify if thienothiazines, which share structural features with the 
phenothiazines, could also inhibit BChE activity and if so, which are the 
structural requirements to do so. 
 
III. To identify compounds that could target two of the important features in AD: 
cholinergic depletion and Aβ aggregates. Thus, a diverse library of natural 
products was tested in vitro for an effect on cholinesterase activity and further 
tested for Aβ aggregation as well as disaggregation. 
 
IV. As we identified cinchona alkaloids as BChE inhibitors in publication III and 
there have previously been reports on cinchona alkaloids as cholinesterase 
inhibitors, we wanted to investigate whether other modifications to the 
cinchona scaffold could also yield BChE inhibitors. 
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3 MATERIALS AND METHODS 
3.1 Compound libraries 
3.1.1 Synthetic compound libraries (I and II) 
The two synthetic compound libraries that have been screened contain a wide variety of 
compounds synthesized by the group of Professor Thomas Erker at the University of Vienna, 
Austria. The larger library consisted of 697 compounds partly containing naturally-present 
scaffolds such as alkaloids, benzanilides, coumarins, flavonoids, imidazoles, and thiophenes 
(I), while the smaller library of 45 compounds focused on thienothiazine derivatives (II). 
The compounds were prepared in cryogenic vials (external threaded polypropylene vials with 
plug seal caps) to a concentration of 20 mM and stored at -20 °C. The compounds were 
diluted in Tris-HCl 50 mM pH 8 before screening at a final concentration of 10 µM. The 
larger library (I) was transferred to 96-well microplates using a Biomek 3000 liquid handling 
station (Beckman Coulter, USA). 
 
3.1.2 Enzo library (III) 
The Enzo® Screen-Well® Natural Product Library (Enzo Life Sciences, Inc. USA) is a 
commercially available compound library that contains 502 natural and naturally derived 
compounds. The concentration of the compounds is 2 mg/ml in DMSO. Compounds are 
maintained at -70 °C and are thawed in a water bath at +37 °C before usage. The library was 
transferred to 96-well microplates using a Biomek 3000 liquid handling station (Beckman 
Coulter, USA) and diluted in Tris-HCl 50 mM pH 8 to concentrations ranging from 0.117 to 
1.624 mM, which means a final concentration between 2.35 and 32.65 µM in the primary 
screening. The sealed plates were stored at +4 °C and screened within one week of 
preparation. 
 
3.1.3 Cinchona alkaloids (IV) 
The small subset of 23 cinchona alkaloids contained commercially available cinchonine and 
cinchonidine and their derivatives synthesized by the group of Professor Reko Leino at the 
Laboratory of Organic Chemistry at Åbo Akademi University, Finland. All compounds were 
prepared as described in section 3.1.1 Synthetic compound libraries. 
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3.2 Biochemical assays (in vitro) 
3.2.1 Ellman’s reaction (I-IV) 
The Ellman’s reaction (Ellman et al., 1961) was used in all publications to detect the anti-
cholinesterase activity of the compound libraries as well as determining the mean inhibitory 
concentrations (IC50) and kinetic mechanisms of the hits. When BChE cleaves 
butyrylthiocholine or when AChE cleaves acetylthiocholine they produce thiocholine and 
butyrate or acetate, respectively. The hydrolytic activity of BChE and AChE can be 
spectrophotometrically detected due to the formation of a coloured anion (5-thio-2-
nitrobenzoate) after the Ellman’s reagent, 5,5’-dithiobis(2-nitrobenzoid acid) (DTNB), reacts 
with the thiocholine. The spontaneous and enzymatic hydrolysis is measured 10 times during 
10 min with Victor2 1420 multilabel counter (PerkinElmer, Finland) at λ=405 nm (I and IV) 
or Varioskan Flash multimode plate reader (Thermo Fisher Scientific, Finland) at λ=412 nm 
(II and III). This is done in a 96-well microplate where the final concentrations of the 
reaction components in the primary screening are: between 2.35 and 32.65 µM of compound 
in Tris-HCl 50 mM pH 8 depending on the compound library screened (see previous section 
3.1 Compound libraries), 1.5 mM substrate in purified water (S-butyrylthiocholine chloride 
(BTCCl) for BChE and acetylthiocholine iodide (ATCI) for AChE), 1.5 mM DTNB in Tris-
HCl 50 mM pH 8 containing 0.1 M NaCl and 0.02 M MgCl × 6 H2O and finally 0.1 % (w/v) 
bovine serum albumin (BSA) in Tris-HCl 50 mM pH 8. The reaction is started by the 
addition of the enzyme at concentrations of 0.350 U/ml for equine BChE (BChE; EC 3.1.1.8, 
from equine serum, Sigma-Aldrich, USA); 0.192 U/ml for recombinant human BChE 
(huBChE; EC 3.1.1.8, expressed in transgenic goat, Sigma-Aldrich, USA); 0.224 U/ml for 
electric eel AChE (AChE; EC 3.1.1.7, from Electric eel, Sigma-Aldrich, USA) and 0.198 
U/ml for human AChE (huAChE; EC 3.1.1.7, from human erythrocytes, Sunnylab, UK). 
Physostigmine was used as a positive control and DMSO:buffer Tris-HCl 50 mM pH 8 was 
used as a solvent control. Galanthamine was also used as a positive control compound. The 
final DMSO concentration during primary screening was 0.05 % in I, II and IV and less than 
0.16 % in III. 
 
3.2.1.1 Potency determination (I-IV) 
To determine the potency of the active compounds the IC50 values were calculated, that is the 
concentration needed to inhibit half of the enzyme activity. This was done by testing the 
inhibitory activity, as described in section 3.2.1 Ellman’s reaction, against BChE and/or 
AChE at several concentrations so as to obtain a concentration-response curve. For this 
purpose a minimum of seven concentrations in at least three replicates were used. In the case 
of selective BChE inhibitors, AChE was also tested up to concentrations of 250 (I and IV) or 
500 (II) µM to determine the selectivity of the active compounds. 
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3.2.1.2 Kinetic measurement (I-IV) 
The mode of action of the hits on BChE or AChE was determined using a minimum of five 
substrate concentrations in the range of 0.065 – 1.5 mM for BTCCl (I, II and IV) and 0.2 – 2 
mM for ATCI (III). Results were fitted into Lineweaver-Burk double-reciprocal (1/V vs 
1/[S]) and Dixon (1/V vs [I]) kinetic plots and apparent Ki values were calculated as follows: 
 
Uncompetitive (Kiuc): 
 
Kiuc = 
Vmax app[I]
Vmax - Vmax app
 
 
Competitive (Kic):  
 
Kic = 
KMVmax app[I]
KM appVmax - KMVmax app
 
 
The kinetic constants determined in absence of inhibitors (I) are marked as KM; Vmax and in 
the presence as KM app; Vmax app. For mixed inhibition a combination of both inhibition types 
occurs. 
 
3.2.2 Thioflavin T (I and III) 
The fluorometric assay using Thioflavin T (ThT) (LeVine, 1993) was used to detect 
aggregation of two peptides as a shift in the emission and excitation spectra (λexcitation = 385 
nm and λemission = 445 nm to λexcitation = 450 nm and λemission = 482 nm) of ThT as it interacts 
with the aggregates. The first peptide was an 11-amino acid fragment containing the 
sequence KLVFF (I) and experimental procedure was conducted as described by Alptüzün et 
al. (2010) at inhibitor concentrations of 2.5, 25 and 250 µM. The second peptide that was 
used was the Aβ1-40 peptide (I and III) and the experiment was carried out as described by 
Liu et al. (2004) with several modifications as described in publication I. 
Nordihydroguaiaretic acid (Ono et al., 2004) and 4-aminophenol (De Felice et al., 2004), 
which are known to inhibit Aβ aggregation, were used as control compounds. Generation of 
fluorescent ThT-positive Aβ1-40 aggregates was accelerated using 1,1,1,3,3,3-hexafluoro-2-
propanol (HFIP) (Catto et al., 2010). In publication I, at higher concentrations, the most 
active compound (6c) was incubated in the buffer/ThT mixture at 37 °C and 1000 rpm for 90 
minutes before protein was added. The IC50 was determined using six concentrations 
between 5 and 50 µM in three replicates. 
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3.2.2.1 Disaggregation of Aβ (III) 
In order to measure the effect of the compound on preformed aggregates, the Aβ1-40 peptide 
was allowed to incubate with ThT for 45 min at 1000 rpm in 37 °C prior to compound 
addition. Before adding the compounds (concentrations between 0.5 and 250 µM) the 
fluorescence was measured to ensure that aggregates had been formed. Resveratrol (Feng et 
al., 2009) was used as a positive control. 
 
3.2.2.2 AChE induced aggregation (III) 
Induction of Aβ1-40 aggregation using the electric eel AChE was performed in analogy to the 
method described by Inestrosa et al. (1996). Aβ1-40 peptide and compound was dissolved in 
0.1 M Tris-HCl, pH 7.4 to a concentration of 230 µM and 1, 5, 10 and 100 µM, respectively. 
Sodium phosphate buffer (0.1 M, pH 8) was used to prepare the electric eel AChE to a final 
concentration of 2.3 µM. The final ThT concentration in the assay was 1.5 µM and 
fluorescence was measured at λexcitation = 440 nm and λemission = 485 nm after 24 h incubation 
at 25 °C with Varioskan Flash multimode plate reader (Thermo Fisher Scientific, Finland). 
 
3.2.3 In vitro cytotoxicity assay (I, II and IV) 
Cell lines of different origins were utilized to determine the cytotoxic effect of the active 
hits: mouse hypothalamic immortalized (GT1-7) (Mellon et al., 1990) (I, II and IV), human 
lung (HL) (I, II and IV), human liver (HepG2) (II and IV) and human epithelial (Caco-2) 
(II, IV) cells. Plates containing cell suspensions of 4 × 105 cells/ml (200 µl) for GT1-7, HL 
and HepG2 and 4.5 × 105 cells/ml (100 µl) for Caco-2 cells were incubated at 37 °C for 24 h. 
After which, 10 (for Caco-2 cells) or 20 µl of culture media was replaced with compound 
solutions at different concentrations (10-100 µM) and incubated for an additional 24 h (I, II 
and IV) or up to 72 h (II) at 37 °C. The culture media was replaced with 20 µM resazurin (In 
vitro Toxicology Assay Kit, resazurin-based, Sigma-Aldrich, US) in PBS for HL, HepG2 
and Caco-2 cells and 25 µM for GT1-7 cells and maintained for 2 h at 37 °C in 5 % CO2 in 
an air-ventilated humidified incubator. Inside viable cells, resazurin is reduced to fluorescent 
resorufin (O'Brien et al., 2000) which was measured using a Varioskan Flash multimode 
plate reader (λexcitation = 570 nm and λemission = 590 nm). Results are expressed as relative 
fluorescence units (RFU) and a reduced resazurin signal indicates that cells are viable. Cells 
not treated with the active hits were used as positive control, only media was used as a 
negative control and 0.5 % DMSO as a solvent control. Cell viability was calculated as a 
percentage of the treated cells in relation to the untreated cells. 
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Cell cultures used in cytotoxicity assay 
Cell lines were cultured using media and supplements as listed in Table 1 in 75 cm2 cell 
culture flasks at 37 °C in 5 % CO2 in an air-ventilated humidified incubator to around 90 % 
confluence. Cells were harvested by adding 0.05 % (v/v) trypsin and 0.02 % (w/v) EDTA in 
PBS for GT1-7, HepG2 and Caco-2 cells and 0.25 % trypsin in PBS for HL cells. 
 
Table 1. Cell culturing media and supplements according to cell line. 
Cell line Media Supplements Publications 
GT1-7 DMEMa) 10 % inactivated FBS I, II and IV 
  50 IU/ml penicillin   
  50 µg/ml streptomycin  
HL RPMI 1640b) 7 % inactivated FBS I, II and IV 
  2 mM L-glutamine  
  20 µg/ml gentamicin  
HepG2 DMEMa) 10 % inactivated FBS II and IV 
  100 IU/ml penicillin  
  100 µg/ml streptomycin  
Caco-2 DMEMa) 10 % inactivated FBS II and IV 
  1 % nonessential amino acids  
  1 % (2mM) L-glutamine  
  100 IU/ml penicillin  
    100 µg/ml streptomycin   
a) Dulbecco’s Modified Eagle Medium (DMEM), Invitrogen, Gibco, Paisley, UK 
b) Biowhittaker, Lonza, Walkersville, USA  
 
3.3 Computational methods (in silico) 
3.3.1 Molecular docking (II, III and IV) 
The crystal structures of AChE that were used were: Torpedo californica AChE PDB code 
1FSS (resolution 3 Å) (Harel et al., 1995) (III) and huAChE PDB codes 1B41 (resolution 
2.76 Å) (Kryger et al., 2000) (II) and 4EY7 (resolution 2.35 Å) (Cheung et al., 2012) (IV). 
The crystal structures of BChE that were used were: huBChE PDB codes 2XQF (resolution 
2.1 Å) (Wandhammer et al., 2011) (II) and 1P0I (resolution 2 Å) (Nicolet et al., 2003) (IV). 
In publication II, ligand building was done using the Chemsketch software (Advanced 
Chemistry Development, Inc.; ACD/Labs) and energy minimized to obtain the geometry-
optimized structure. The Autodock4.2 (Morris et al., 2009) program was used to perform 
molecular docking of the ligand into the active site of huBChE and huAChE. In III and IV 
the proteins were prepared using the Protein Preparation Wizard in Schrödinger (Schrödinger 
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Suite 2011 Protein Preparation Wizard; Epik version 2.2, Ligprep 2.5, Glide 5.7, New York). 
The ligands were drawn in Maestro and prepared using the Ligprep module with an MMFF 
force field. For our docking studies the option to dock flexibly with standard precision mode 
(III) and extra precision (XP) mode (IV) was selected. 
 
3.3.2 ChemGPS-NP (I-IV) 
The compound libraries were analysed using the chemical global positioning system 
(ChemGPS) modified to also take into account biologically relevant natural products (NP), 
ChemGPS-NP (Larsson et al., 2007; Rosén et al., 2009). PC scores were obtained using 
SMILES for the compound libraries that had been acquired using web based programs 
ChemSpider (www.chemspider.com) or Molinspiration Chemoinformatics v2009.01. 
(www.molinspiration.com). Salts, hydration information, counter-ions and tautomeric 
structures were excluded. In our analysis only the first four of the eight dimensions were 
used, namely PC1 to PC4, mainly describing size, aromaticity, lipophilicity and flexibility 
and visualized using Grapher 2.1 software (MacOS X, US). 
 
3.3.3 Statistical analysis (I-IV) 
The concentration of the compounds in the primary screening was 10 µM (I, II and IV) and 
2.35 - 32.65 µM (III). Compounds were tested in a single-well composition in the primary 
screening and at least two replicates of each concentration were used for the potency 
determination and kinetic measurement and four replicates in the cytotoxicity assays. The 
potency determination experiment was repeated at least twice and IC50 values were 
calculated using non-linear regression analysis (sigmoidal fitting with variable slope) in 
GraphPad Prism v.4.0 (I and III) and v. 5.0c (II and IV) for Mac (GraphPad software Inc., 
US). 
 
The assay performance was monitored using typical statistical parameters (Z’ factor, S/B 
ratio, S/N ratio and CVA) as described by Zhang et al. (1999), Bollini et al. (2002) and 
Iversen et al. (2006): 
 
Z’ factor: 
Z' = 1 - 3SDS + 3SDB
|XS - XB|  
 
S/B ratio: 
S/B = 
XS
XB
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S/N ratio: S/N = XS - XB
�SDS2 - SDB2  
 
CVA CVA = SDSXS - XB 
 
 
The equations above describe the relationship between the mean values and standard 
deviations of the minimal (XB and SDB) and maximal (XS and SDS) signals as determined by 
measuring the spectrophotometric absorbance in the solvent (negative) control wells at one 
(minimal) and ten (maximal) minutes after enzyme addition. 
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4 RESULTS 
4.1 Assay performance (I-IV) 
The assay performance was monitored using the statistical tools S/N ratio (Bollini et al., 
2002), S/B ratio, Z’ factor (Zhang et al., 1999) and CVA (Iversen et al., 2006) and the 
theoretical hit limit was set at three times the standard deviation of the maximal signal 
(negative controls). In publication I, II and IV acceptance parameters were set as Z’ > 0.5, 
S/N > 7 and S/B > 4 and the empirical hit limit was set at 50 % inhibition in order to identify 
compounds with IC50 ≤ 10 µM. In publication III acceptance parameters were set as Z’ > 0.5, 
S/N > 15 and S/B > 15 and the theoretical hit limit was set at 40 % of inhibition. However, 
since the screening was planned at an average compound concentration in the micromolar 
range (17.5 µM), the threshold was empirically set higher, at 50 % inhibition, to identify 
more potent inhibitors. Using the Ellman’s kinetic reaction good statistical parameters are 
obtained with a good signal window. The absorbance was measured using Victor2 1420 
multilable counter (I and IV), which required manual enzyme addition, and Varioskan Flash 
multimode plate reader (II and III), with automatic enzyme dispensing. Differences in the 
minimal and maximal signal can be observed between the two systems due to the time delay 
that occurs using Victor2 (Figure 10), however, this did not affect the quality of the assay as 
the separation band was still large and Z’ values were ≥ 0.5. On average, throughout the 
primary screening of all compound libraries, the Z’ was 0.69 ± 0.14. 
 
Figure 10. Variance between wells in maximal and minimal signal using Victor2 1420 multilable 
counter (405 nm) and Varioskan Flash multimode plate reader (412 nm). Manual enzyme addition 
using Victor2 causes more variance between the wells in addition to a delayed measurement of the 
initial kinetics which was eliminated using Varioskan with automatic enzyme dispensing. However, a 
good signal window using the Ellman’s reaction was obtained using both plate readers. 
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4.2 Primary cholinesterase screening results (I-IV) 
In publications I-IV a total of 1267 compounds was screened for inhibitory activity on 
equine BChE and electric eel AChE. The libraries contained natural molecules as well as 
compounds synthesized based on naturally-present scaffolds. The libraries used in this work 
can be divided into two categories; the larger and more diverse compound libraries (I and 
III) and the smaller, more focused libraries (II and IV). The frequency distribution of the 
BChE and AChE activity can be seen in Figure 11. Most of the compounds had no activity 
on the enzymes thus clustering around 100 % enzyme activity. A total of 27 BChE inhibitors, 
seven AChE inhibitors and three dual inhibitors were found, as summarized in Table 2. 
Additionally, the libraries contained compounds that showed some inhibitory activity but 
which however were under the applied hit limit and were therefore excluded from further 
investigations. 
 
A) 
 
B) 
 
Figure 11. Summary of the frequency distribution of A) BChE and B) AChE activity during primary 
screening of all 1267 compounds (I-IV). The average activity for BChE was 96 ± 14 % and for AChE 
95 ± 11 %. 
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Table 2. Size of screening libraries, number of inhibitors found and hit rate. 
Publication Compounds Concentration Inhibitors of Active compounds Hit ratea) 
    (µM) BChE AChE Dual     
I 697 10 5 0 0 5 0.007 
II 45 10 6 0 0 6 0.13 
III 502 2.35-32.65 14 6 3 23 0.05 
IV 23 10 2 1 0 3 0.13 
Total 1267   27 7 3 37 0.03 
a) Calculated as total amount of inhibitors divided by total amount of compounds  
 
4.3 Characterization of active compounds (I-IV) 
4.3.1 Potency determination and structural optimization 
Potency determination was performed on the compounds that inhibited 50 % of the enzyme 
target at the screening concentration (I-IV), with some exceptions as follows: in publication 
III already well-known cholinesterase inhibitors (galanthamine, ebelactone B, huperzine A 
and physostigmine) and compounds that were unstable in the assay condition (solasodine, 
tetrahydroalstonine and harmine) were excluded. A summary of the determined potencies of 
compounds in publication I-IV can be found in Table 3. In publication I, structural 
optimization was carried out on the most active chemical class, the diarylimidazoles (1a-c) 
and a total of 12 new compounds (6a-c, 9a-i) were tested for their BChE inhibitory activity. 
These results have also been included in Table 3. In total, 12 compounds have been found 
with inhibitory potencies under 1 µM against BChE. Some of the most active compounds 
were also tested against the huBChE and huAChE. 
 
Table 3. Potencies of the original hits presented in publications I-IV. 
Publication Compound IC50 (µM) 
    BChE huBChE AChE huAChE 
I 1a 3.6 ± 0.7 n.t. >250 n.t. 
 1b 1.5 ± 0.4 n.t. >250 n.t. 
 1c 0.20 ± 0.03 n.t. >250 n.t. 
 6a >10 n.t. >250 n.t. 
 6b >10 n.t. >250 n.t. 
 6c 0.10 ± 0.01 1.1 >250 n.t. 
 9a 12 ± 2 n.t. >250 n.t. 
 9b 1.8 ± 0.1 n.t. >250 n.t. 
 9c 0.68 ± 0.05 n.t. >250 n.t. 
 9d 0.86 ± 0.04 n.t. >250 n.t. 
 9e 0.98 ± 0.04 n.t. >250 n.t. 
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 9f 3.4 ± 0.1 n.t. >250 n.t. 
 9g 0.18 ±0.06 n.t. >250 n.t. 
 9h 3.2 ± 0.5 n.t. >250 n.t. 
  9i 0.16 ± 0.07 n.t. >250 n.t. 
II 3a 1.4 ± 0.4 17 ± 3 >500 49 ± 8 
 3b 0.17 ± 0.03 20 ± 4 110 ± 14 88 ± 1 
 3c 3.8 ± 0.6 7.2 ± 3.2 210 ± 30 300 ± 59 
 3d 0.49 ± 0.02 17 ± 4 140 ± 3 240 ± 6 
 3e 0.34 ± 0.03 2.2 ± 0.4 220 ± 11 120 ± 9 
  3f 0.037 ± 0.07 0.51 ± 0.07 140 ± 3 53 ± 1 
III Peganole 11 ± 0 > 20 n.a. n.t. 
 Vasicine 2.5 ± 0.4 3.1 ± 0.8 n.a. n.t. 
 Desoxypeganine 12 ± 0 n.t. 12 ± 0 n.t. 
 Nitrarine 11 ± 0 9.0 ± 0.2 n.a. n.t. 
 Hirsutine 5.0 ± 0.3 2.0 ± 0.0 n.a. n.t. 
 Rauwolscine 8.4 ± 0.5 14 ± 1 n.a. n.t. 
 Catharanthine 5.2 ± 0.2 3.2 ± 0.1 n.a. n.t. 
 Sevedindione 3.7 ± 0.3 0.3 ± 0.0 n.a. n.t. 
 Veratramine 11 ± 1 19 ± 1 n.a. n.t. 
 E6 Berbamine 4.2 ± 0.2 2.1 ± 0.1 n.a. n.t. 
 
Oxyacanthine 
sulfate 4.1 ± 0.2 1.9 ± 0.1 n.a. n.t. 
 Quinidine  7.4 ± 0.0 1.2 ± 0.1 n.a. n.t. 
 Himbacine n.a. n.t. 23 ± 1 n.t. 
 Palmatine  n.a. n.t. 4 ± 0.1 1.7 ± 0.1 
 Berberine  n.a. n.t. 2.7 ± 0.2 0.6 ± 0.0 
  Chelerythrine  6.3 ± 0.9 10 ± 0 3.8 ± 0.2 1.5 ± 0.1 
IV 11 9.8 ± 0.3 34 ± 5 21 ± 2 120 ± 29 
  15 0.56 ± 0.14 0.24 ± 0.04 >250 >250 
Controls Galanthamine 17 ± 1 30 ± 0 1.6 ± 0.0 n.t. 
 Physostigmine 2.1 ± 0.5 4.6 ± 0.0 1.8 ± 0.2
a) n.t. 
n.a. - not active 
n.t. - not tested 
a) previously reported by our group (Järvinen et al., 2011) 
 
4.3.2 Kinetic mechanisms 
The kinetic mechanism of the most active compounds against BChE or AChE was 
determined and Ki values calculated using Lineweaver-Burk double reciprocal plots. In 
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Table 4, the most active hit from each publication is presented, one uncompetitive and three 
mixed inhibitors were found, all with Ki values in the lower micromolar range.  
 
Table 4. Structure and kinetic mechanism of the most potent compounds according to publication. 
Publication Compound Structure Enzyme/ Kinetic mechanism 
      Ki values 
I 6c 
 
 
 
equine BChE/ uncompetitive 
Ki = 0.073 ± 0.011 µM 
II 3f 
 
 
 
huBChE/ mixed 
Kic = 0.62 ± 0.04 µM        
Kiuc = 0.064 ± 0.002 µM 
III Chelerythrine 
 
 
 
huAChE/ mixeda) 
Kic = 0.32 ± 0.08 µM        
Kiuc = 1.1 ± 0.1 µM 
   
IV 15 
 
equine BChE/ mixed 
Kic  = 0.85 ± 0.26 µM       
Kiuc = 1.7 ± 0.5 µM 
      
a) Chelerythrine is a dual inhibitor with higher affinity for AChE than BChE 
 
4.3.3 Cytotoxicity 
Potential cytotoxic effect of the active compounds was evaluated using cell lines with 
different origins. In publication I the most active compound (6c) was tested in GT1-7 and 
HL cells and was not seen to affect cell viability at concentrations up to 50 µM. In 
publication II the cytotoxicity of the entire library was tested on GT1-7 immortalized 
neurons. Four compounds (3i, 3j, 6b and 6d) reduced cell viability under 80 % but none less 
than 75 % at 10 µM. The most active compounds (3a-f) were further tested at 10 and 50 µM 
for 48 and 72 hours in the same cell line to exclude delayed cytotoxic effect. Only one 
compound (3d) showed time-dependent cytotoxicity as it significantly reduced cell viability 
at 50 µM after 72 hours. The most active compound (3f) was also tested in HL, Caco-2 and 
HepG2 cells up to 100 µM with no cytotoxic effect observed. In publication IV the 
cytotoxicity of 11 and 15 was tested in GT1-7, HL, Caco-2 and HepG2 cell lines. Cell 
viability was reduced by 11 at the higher concentrations (80 and 100 µM), while 15 did not 
significantly reduce cell viability. 
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4.4 Structure-activity relationship and pharmacophore model (I and 
II) 
A total of 15 compounds were selected for structure-activity relationship (SAR) studies in 
publication I. This included the original three active hits 1a-c and the derivatives 6a-c and 
9a-i (activities shown previously in Table 3). Modifications included alkoxy and thioether 
groups and phenyl versus thienyl systems. Substitutions on both phenyl rings were not 
beneficial for BChE inhibition as this resulted in the lowest inhibitor activity. Substitution in 
meta position was favoured over ortho position and the results showed that the alkoxy 
residues in the meta position on the phenyl ring were favoured in the following order: ethoxy 
< methoxy < isobutoxy < butoxy < propoxy. 
 
In publication II the compounds were clustered into eight groups, A-H, depending on their 
structures (Table 1 in publication II) and the active compounds all belonged to the same 
group, group C. A pharmacophore model based on the results from the thienothiazine BChE 
screening as well as the previous results by Darvesh et al. (2010) was proposed (Figure 3 in 
publication II). We concluded that two hydrophobic areas, a hydrogen bond acceptor and 
donor, an alkanediyl linker with a minimum of two carbon atoms and distal basic nitrogen 
are required for selective BChE inhibition using the thienothiazine scaffold. 
 
4.5 Prevention and destruction of Aβ aggregates (I and III) 
In publication I and III the ability of the active compounds to inhibit Aβ aggregation was 
tested. In publication I the active compounds (1a-c) were first tested on the short peptide 
HHQKLVFFAED and showed a concentration-dependent inhibition of Aβ aggregation. At 
250 µM inhibitory values of 45, 58 and 65 % inhibition, respectively, were obtained. They 
were further tested on the Aβ1-40 peptide and displayed similar values at 250 µM; 57, 38 and 
62 %, respectively. Lead optimization of the original hits resulted in an even more potent 
inhibitor of Aβ1-40 aggregation (6c) with an IC50 value of 5.8 µM. The most active 
cholinesterase inhibitor in publication III, chelerythrine, was proven to inhibit the 
aggregation of the Aβ1-40 peptide with an IC50 value of 4.2 ± 0.4 µM. Two reference 
compounds were used; nordihydroguaiaretic acid showed a potency value of 18 µM and 4-
aminophenol a potency value of 83 µM on inhibiting Aβ1-40 aggregation. 
 
Chelerythrine (III) was further tested if it could inhibit electric eel AChE-induced 
aggregation of Aβ. The concentration tested was 5, 10 and 100 μM and produced an 
inhibition of 49, 65 and 88 % of Aβ aggregation. Propidium iodide was used as a reference 
compound and showed 93.1 ± 2.2 % inhibition at 100 µM. We also tested if chelerythrine 
could destruct preformed Aβ aggregates as this would be a relevant feature in AD 
pharmacotherapy. In this case Aβ was allowed to aggregate 45 minutes before addition of 
chelerythrine and after 45 min incubation with the compound an IC50 of 13.0 ± 2.9 µM was 
obtained. Resveratrol was used as a positive control and determined to have an IC50 of 81.8 ± 
3.7 µM. 
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4.6 Molecular docking studies (II, III and IV) 
Molecular docking studies were performed in order to get insight into the structural features 
required for cholinesterase inhibition. The results from the docking studies of the most active 
compounds in publication II and IV can be found in Figure 12 and in publication III in 
Figure 13. In publication II, 3f was docked into 2XQF (huBChE) (Wandhammer et al., 
2011) and 1B41 (huAChE) (Kryger et al., 2000) using the Autodock4.2 program to specify 
interactions with huBChE but also to get some insight into the selectivity of the compound. 
In the huBChE crystal structure, the important and structurally conserved water molecules at 
the active site are W2139, W2138, W2129, W2067, W2170, W2066, W2082, W2128 and 
W2085, and are in Figure 12 denoted as W1, W2, W3, W4, W5, W6, W7, W8 and W9, 
respectively. In the huAChE crystal structure the comparable water molecules are W737, 
W659, W664, W670 and W663 and are denoted as W1, W2, W4, W5 and W8, respectively. 
In huBChE, two strong hydrogen bonding interactions are formed between the oxygen atom 
of the carbonyl group of 3f with the catalytic site residues Ser-198 and His-438, while in 
huAChE, hydrogen bonding forms between two different functional groups of compound 3f 
(an amide group (NH) and a protonated tertiary amine group) and Tyr-337 (Figure 12). 
 
In publication IV, the two most active compounds were docked into huAChE and huBChE in 
order to identify structural differences in enzyme specificity and inhibitory activity. In this 
case the crystal structure with PDB ID 1POI was used for huBChE (Nicolet et al., 2003) and 
4EY7 for huAChE (Cheung et al., 2012) in order to dock the active compound 15. The active 
site of 1POI consists of residues Asp-70, Trp-82, Gly-116, Gly-117, Glu-197, Ser-198, Ala-
199, Trp-231, Leu-286, Ser-287, Val-288, Tyr-332 and His-438 and conserved water 
molecules influencing the ligand binding W736, W786, W811, W825, W839, W875, W910, 
W919, W1042, W1076, W1177 are shown as W1, W2, W3, W4, W5, W6, W7, W8, W9, 
W10 and W11 respectively. The active site of 4EY7 consists primarily of residues Tyr-72, 
Trp-86, Tyr-124, Glu-202, Ser-203, Ala-226, Phe-295, Tyr-337, Tyr-341 and His-447 and 
conserved water molecules W728, W737, W856, W931, W952, W953, and W954 are 
depicted as W1, W2, W3, W4, W5, W6, and W7 respectively. It is plausible that 15 forms π-
π stacking interactions with Trp-82 in huBChE while it is not able to enter the active site 
gorge of huAChE (Figure 12). The docking scores for 11 and 15 within the active sites of 
huBChE and huAChE were −7.549 and −6.515 and −8.813 and −4.345, respectively. 
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Figure 12. Docking of the most active compound in publication II and IV in huBChE and huAChE. In 
publication II the crystal structures 2XQF (huBChE) (Wandhammer et al., 2011) and 1B41 (huAChE) 
(Kryger et al., 2000) were used while in publication IV the crystal structures 1POI (huBChE) (Nicolet 
et al., 2003) and 4EY7 (huAChE) (Cheung et al., 2012) were used. 
 
In publication III, chelerythrine was docked using the crystal structure of 1FSS (Torpedo 
californica AChE) (Harel et al., 1995) for which the active site consists of residues Tyr-70, 
Trp-84, Gly-118, Gly-119, Glu-200, Ser-201, Ala-226, Trp-279, Tyr-327, Phe-330 and His-
440. Chelerythrine shows hydrogen bonding interaction with Tyr-130 and π-stacking 
interactions with Tyr-121 and Tyr-334 PAS residues. Conserved water molecules 710, 718, 
722, 728 are denoted as W1, W2, W3 and W4 in Figure 13 and are found to play an 
important role for binding inhibitors within the active site. 
 
Publication II 
3f 
Publication IV 
15 
huBChE huAChE 
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Figure 13. Molecular docking of the most active compound, chelerythrine, in publication III using 
Torpedo californica AChE (1FSS) (Harel et al., 1995). 
 
4.7 ChemGPS-NP and chemical space (I-IV) 
The compound libraries were all mapped into 3D graphs using PC scores obtained by 
ChemGPs-NP in order to visualize and analyse the chemical space occupied by our active 
and non-active compounds. In Figure 14 the compound libraries (I-IV) have been clustered 
according to their size in order to facilitate the analysis. As can be seen the screening 
libraries occupy a wide space with different molecular sizes and different degrees of 
lipophilicity, aromaticity and flexibility.  
 
The synthetic library including the diarylimidazoles (I) (yellow dots) contains compounds 
mostly on the negative side of PC1, positive side of PC2, both sides of PC3 and positive side 
of PC4. The Enzo® Screen-Well® Natural Product Library (green dots) (III), on the other 
hand includes compounds with properties that expands to all sides of the four dimensions 
included here (PC1-4) (Figure 14A-B). However, they tend to cluster more on the positive 
side of PC1 (higher molecular size) and negative side of PC4 (more rigid). 
 
In Figure 14C-D, the purple dots represent the synthetic library containing derivatives of the 
thienothiazine type (II) while the blue dots represent the cinchona alkaloid library (IV). 
Consisting of a small group of derivatives, as already mentioned, they occupy a quite narrow 
chemical space. Both of these libraries contain compounds that span throughout the positive 
and negative side of PC1 (varying molecular size) while mostly being on the positive side of 
PC2 and PC3 (more aromatic and lipophilic). Some of the thienothiazine groups (A and F, 
Figure 1 in publication II) contained small compounds that were on the polar side (negative 
PC3). Both libraries have a trend of increasing lipophilicity with size. When including 
flexibility (PC4) the compounds within the libraries tend to cluster together, showing 
similarities in the flexibility. However, there is a difference between the cinchona alkaloid 
derivatives and the thienothiazine derivatives, with the former occupying the negative side of 
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PC4 (blue dots, more rigid) and the latter the positive side (purple dots, more flexible). In 
Figure 15, the active compounds have been indicated in red and are compared to the 
chemical space occupied by all compounds included in the primary screening. The active 
compounds mostly span the negative side of PC1 and PC4 and the positive side of PC2 and 
PC3.  
 
A)       B) 
    
 
C)       D) 
     
 
Figure 14. Three dimensional visualization of the chemical space occupied by the compounds included 
in the different screening libraries using ChemGPS-NP. The larger synthetic library containing the 
diarylimidazoles (I) is visualized using yellow dots, the small synthetic thienothiazine library (II) using 
purple dots, the Enzo® Screen-Well® Natural Product Library (III) using green dots and the cinchona 
alkaloid synthetic library (IV) using blue dots. In A) the first three dimensions; PC1 (size), PC2 
(aromaticity) and PC3 (lipophilicity) of the larger compound libraries (I and III) are shown and in B) 
the fourth dimension (PC4) is taken into account. In C) and D) the two smaller libraries (II and IV) are 
similarly shown. 
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Figure 15. Identification of the chemical space occupied by the active cholinesterase inhibitors using 
ChemGPS-NP. The compound libraries are indicated with white dots and the active compounds are 
visualized with red dots. 
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5 DISCUSSION 
It is estimated that in the world there is one new case of AD every seven seconds (Massoud 
and Gauthier, 2010), devastating the life of a whole family. Current treatments offer little 
relief and thus novel mechanisms and new approaches are required; however, CNS projects 
in general are prone to be less successful, more expensive, take a longer time as well as being 
scientifically more demanding, and so it seems also when it comes to the development of 
new AD pharmacotherapy. So far the patients of AD have two classes of drugs to choose 
from, the cholinesterase inhibitors and an NMDA receptor antagonist, both providing 
symptomatic relief but with several adverse effects. Considering that cholinesterase 
inhibitors are the first-line therapy for AD, and will probably continue to be so for many 
years, developing next generation cholinesterase inhibitors is important. For a long time, 
BChE was a neglected target in AD drug discovery as it has a lower activity than AChE and 
exist in the “wrong” areas in the healthy human brain (Greig et al., 2005). However, changes 
that occur in the AD brain call for a reassessment of the role of BChE and it has been 
demonstrated that BChE inhibitors may offer a new approach to managing AD (Giacobini, 
2004; Greig et al., 2005; Lane et al., 2006). Considering the potential therapeutic benefit that 
BChE inhibitors may offer in the future, the focus of this work has been on finding novel 
BChE inhibitors. 
 
Evolution has provided nature with a diversity of natural products that has not only been 
beneficial for the plants producing them but also for humans as plant extracts were the first 
medicines available to treat ailments (Ganesan, 2008). Natural products still play an 
important role in drug discovery as half of the current drugs have their roots in nature 
(Newman and Cragg, 2012) and in fact two out of four AD drugs have a natural origin 
(galanthamine, from Galanthus woronowii Losinsk., and rivastigmine, based on the structure 
of physostigmine from Physostigma venenosum Balf.). Although natural products are 
considered to have an advantage as they have been shaped by evolution to possess biological 
activity (Koch and Waldmann, 2005), natural products do have some limitations as well, 
such as: crude natural product extracts are not suitable for HTS, there are difficulties in 
collecting and isolating the natural compounds and, after identifying an active compound, 
obtaining a supply of the bioactive compound in larger amounts (Kingston, 2011). It is no 
surprise that natural products therefore often have to be synthesised, such as, for example, 
galanthamine (Marco-Contelles et al., 2006), as this is also generally a more efficient and 
economical way. During this study we therefore screened for cholinesterase inhibitors among 
compound libraries containing compounds with natural origin or synthetic compounds partly 
based on natural scaffolds, as we believe these types of compounds gives an advantage in 
finding new bioactive compounds with the possibility to conduct further structural 
optimization. 
 
The solvent used for preparing the compound libraries was DMSO, as this is the most 
common solvent used for storing compound libraries (Di and Kerns, 2006). It is previously 
known that DMSO has an effect on cholinesterase activity (Jagota, 1992; Di Giovanni et al., 
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2008); however, as the DMSO concentration was kept at a low final concentration (0.05 % 
and 0.16 %) during the primary screening this did not affect the screening outcome. The 
theoretical hit limit was set as three times the standard deviation of the maximal signal 
(negative controls, samples containing the uninhibited enzyme) as this ensures a clear 
separation between the variation of the maximal signal and the actual active compounds 
(Zhang et al., 1999). However, the limit was in some cases (I-III) further increased so as to 
ensure a high activity of the identified compounds as well as facilitate the management of the 
compounds during their characterization. The hit rate during primary screening is usually < 
1 % (Coma et al., 2009; Posner et al., 2009; Ilouga and Hesterkamp, 2012) and in our case it 
was 0.7 (I), 13 (II and IV) and 5 % (III). The higher hit rates in publication II and IV are 
due to the fact that the screened libraries are smaller and more focused. More specifically, 
this means they contained compounds with specific structures that were expected to have 
activity. In publication III, where the natural products library was used, the hit rate was also 
high. It is known that the hit rate in natural products libraries are usually higher as natural 
products, as noted earlier, have been “designed” by nature to possess bioactivity (Koch and 
Waldmann, 2005). Moreover, this library contained a set of already well-known 
cholinesterase inhibitors. 
 
The assay using the Ellman’s reagent is considered the most appropriate assay for testing 
cholinesterase activity (Di Giovanni et al., 2008), it has been extensively applied with 
different modifications (e.g. Carolan et al., 2008; Rizzo et al., 2008; Järvinen et al., 2010) 
and is considered to be reliable and robust. Nevertheless, to ensure that the assay performed 
with high quality during the screening process, statistical parameters indicating the 
performance of the assay [S/N ratio (Bollini et al., 2002), S/B ratio, Z factor (Zhang et al., 
1999) and CVA (Iversen et al., 2006)] were applied. According to Zhang et al. (1999), in a 
biochemical assay, a Z’ value ≥ 0.5 is considered a good-to-excellent assay where Z’ = 1 is 
the highest value (the ideal assay). Thus during our screening we set the criteria for Z’ at 0.5, 
however most of the time the Z’ was well above this value. The S/B ratio indicates the ratio 
between the average maximal and minimal signal but does not take into account the variance 
of the two signals. The S/N ratio (Bollini et al., 2002), on the other hand, also reflects the 
differences between the standard deviations of the maximal and minimal signal, thus giving a 
more accurate view of the dispersion of the signal. A higher value indicates a larger 
separation between the maximal and minimal signal as well as less dispersion of the values. 
 
During this thesis project we have found a total of nine chemical groups that inhibit BChE: 
diarylimidazoles, benzanilides (I), thienothiazines (II), quinazolines, indoles, steroid 
alkaloids, compounds with a polycyclic ring system, an isoquinoline (III) and cinchona 
alkaloids (III and IV). In the past, several chemical classes have been identified as BChE 
inhibitors (e.g. Greig et al., 2005; Elsinghorst et al., 2006; Decker et al., 2008; Carolan et al., 
2010; Darvesh et al., 2010; Nawaz et al., 2011). Some of the different chemical classes found 
during this thesis project have previously been associated with either cholinesterase 
inhibition or other biological activities. The imidazole core structure, for example, is 
commonly present in drug molecules (Bemis and Murcko, 1996) and has also been present in 
previously reported cholinesterase inhibitors (Andreani et al., 2008; Kovárová et al., 2010). 
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Other of these chemical classes that have been shown to possess activity against 
cholinesterases are: quinazoline (e.g. Decker et al., 2008; Chen et al., 2011)), indole (e.g. 
Ismail et al., 2012; Khorana et al., 2012; Passos et al., 2013), steroid alkaloids (e.g. Devkota 
et al., 2008; Yang et al., 2012), isoquinoline (e.g. Shan et al., 2011; Huang et al., 2012; Peng 
et al., 2012) and cinchona alkaloids (Kambam et al., 1987; Chemnitius et al., 1997; Nawaz et 
al., 2011). This, however, does not imply that the compounds found during this project 
would not be of interest, quite the contrary. The substitutions of the different chemical 
classes found in this project vary considerably from the previously published compounds and 
combining this previous data of cholinesterase inhibitors with our results may aid in 
developing even more potent inhibitors; as was the aim in publication II with the 
thienothiazines and their structural relationship to the phenothiazines, (Darvesh et al., 2005; 
Darvesh et al., 2007; Darvesh et al., 2010). No reports on benzanilides (I) or thienothiazines 
(II) as cholinesterase inhibitors were found while searching the literature, thus suggesting 
that this is the first time compounds of these chemical structures have shown activity against 
cholinesterase. In fact, it was among the thienothiazines (II) that we found the most potent 
inhibitor during this study, with IC50 values of 37 nM against BChE and 510 nM against 
huBChE. This was compared to the controls physostigmine and galanthamine which had IC50 
values of 2.1 and 17 µM, respectively, against BChE (Table 3). As a comparison, in Table 
5, a collection of previously published BChE inhibitors have been listed along with their 
potencies and the control used in that study. In this work the potencies ranged from 0.037- 
2.5 µM among the most potent BChE inhibitors in publications I-IV (Table 3). 
 
Table 5. Published cholinesterase inhibitors with selectivity towards BChE according to 
their chemical class; selected examples. 
Chemical class Reference ID IC50 (µM) Ki (µM) Control IC50 (µM)b) 
Benzofuran  (Rizzo et al., 2008) 1 0.28a)  RIV: 0.30
a) 
Cinchona alkaloid (Nawaz et al., 2011) 5 0.34 0.4 PHY: 1.85 
Cymserine  (Greig et al., 2005) BNC 0.001a)  n.d. 
Isosorbide  (Carolan et al., 2010) 5 0.00015a)  PHY: 0.019
a) 
Phenothiazine  (Darvesh et al., 2007) 23  0.0035
a) GAL: Ki 2.09a) 
Quinazolinimine (Chen et al., 2011) 33 0.003  GAL: 8.4 
Steroid alkaloid (Devkota et al., 2008) 4 0.3  GAL: 8.2 
n.d. - not determined 
a) Enzyme origin: human 
b) RIV: Rivastigmine, PHY: Physostigmine and GAL: Galanthamine  
 
The isosorbide compound (Carolan et al., 2010) is the most potent BChE inhibitor to date. 
However, these types of inhibitor seem to be limited as they are rapidly degraded by 
carboxylesterases in mouse plasma, restricting their use in mice AD models (Dillon et al., 
2010). The cinchona alkaloid (IV) we found was in the same range as the most active by 
Nawaz et al. (2011), only our compounds required less extensive substitutions to achieve the 
same goal, and by additional hit refinement this potency could most probably be further 
improved. The most active diarylimidazole (I) had an IC50 value of 0.1 µM (Table 3) and in 
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the Enzo® Screen-Well® Natural Product Library (III) (Enzo Life Sciences, Inc. USA) the 
most active BChE inhibitor was vasicine with an IC50 value of 2.5 µM. However, although 
vasicine was the most potent compound against BChE (III), further investigation into the 
possible effect of the compounds on Aβ aggregates, made us turn our attention towards 
chelerythrine, an isoquinoline with a BChE IC50 value of 6.3 µM. As AD is a multifactorial 
disorder and thus does not seem to fit into the category “one target-one disease”, finding 
bifunctional drugs, that is, one drug that can modify several targets of the disease at the same 
time, can prove an advantage. Therefore we also paid attention to the amyloid hypothesis, 
and the beneficial effect that inhibiting cholinesterase and Aβ aggregation may convey. 
 
BChE and AChE are known to exist in Aβ plaques and neurofibrillary tangles (Mesulam et 
al., 1987) but while AChE induces Aβ fibril formation, BChE has not shown this inducing 
mechanism (Inestrosa et al., 1996) and in fact the imperfect amphipathic characteristics of 
the C-terminal of the human BChE has actually shown to slow down the formation of Aβ 
fibrils in vitro (Diamant et al., 2006). It has also been shown that Aβ plaques can occur in the 
brain of older adults, but is only associated with BChE in the AD brain (Darvesh, 2013) and 
observations in a transgenic mouse model of AD point to an involvement of BChE in the 
maturation of Aβ plaques (Darvesh et al., 2012). Nevertheless, the link between BChE 
inhibition and Aβ fibril formation is still unclear (Diamant et al., 2006; Podoly et al., 2010). 
Compounds inhibiting Aβ fibril formation/aggregation that have previously been found are 
e.g. 4-aminophenol (De Felice et al., 2004), nordihydroguaiaretic acid (Ono et al., 2004), 
propidium iodide (Bartolini et al., 2003), 4-(2-(2,6-dichlorobenzylidene) hydrazinyl)-1-(3-
phenylpropyl) pyridin-1-ium bromide (Alptüzün et al., 2010) and 4-hydroxyindole (Cohen et 
al., 2006). By using bifunctional compounds the amount of drugs a patient may need to take 
during the day is reduced as well as the risk of drug-drug interactions, and the 
pharmaceutical companies can focus on developing one drug instead of two. However, it 
may become challenging to manage the dose needed to achieve the different activities 
simultaneously (Morphy and Rankovic, 2005). 
 
During this thesis project, two compound classes were found to inhibit Aβ aggregation in 
vitro, the diarylimidazoles (I) and the isoquinolines (III), making them bifunctional 
compounds and thus more attractive from a drug discovery perspective. In addition, both 
compounds were found to be even more potent (IC50 values 4-6 µM) than the control 
compounds, nordihydroguaiaretic acid (IC50 18 µM) and 4-aminophenol (64 % inhibition at 
250 µM). Although the ThT assay is known to produce variations between runs and Aβ 
protein batches the ThT assay has been extensively used for quantification of Aβ aggregation 
(Reinke and Gestwicki, 2011; Sabate and Saupe, 2007). In publication I, the short peptide 
HHQKLVFFAED (Alptüzün et al., 2010) was first used before testing with the full peptide 
Aβ(1–40) peptide. The sequence KLVFF, which is present in this short peptide, has been 
defined as the fibril forming sequence (Tjernberg et al., 1996; Gazit, 2005), thus, using the 
shorter peptide, a first view of the compounds anti-amyloid properties can be assessed before 
continuing with the full peptide. Compounds exhibiting both cholinesterase and amyloid-β 
inhibitory activities have previously been published, i.e. benzofuran-based inhibitors with an 
IC50 of 7.0 µM (Rizzo et al., 2008), phenylthiazole–tacrine hybrid inhibitors with activity of 
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72 % inhibition at 20 µM (Wang et al., 2012) and tacrine-coumarine hybrids 68 % inhibition 
at 20 µM (Xie et al., 2013). All of these Aβ aggregation studies have focused on the 
inhibition of the formation of the Aβ aggregates; however, considering that the Aβ 
aggregates have already formed in the AD brain, the destruction of the aggregates could be 
an additional and even more relevant feature. Chelerythrine (III) was found to destroy 
preformed aggregates (disaggregation) with an IC50 of 13 µM. Thus, chelerythrine is a potent 
inhibitor of AChE and BChE, it inhibits Aβ aggregation and AChE-induced aggregation 
(48.5 % at 5 µM) and it also has the ability to disaggregate preformed Aβ aggregates. 
Chelerythrine is therefore an attractive compound for future drug discovery and 
development. 
 
During the drug discovery process it is very important to continue with the right compounds 
so as to minimize failure at later stages. Thus series of tests are made to eliminate hits with 
unbeneficial properties. One problem that reoccurs is safety issues regarding drug candidates, 
and testing for cytotoxicity at an early stage is therefore important. During this thesis project 
the active compounds have been tested against different cell lines to assess their cytotoxic 
effect. As the compounds are aimed at targeting the brain the cytotoxic effect on 
immortalized neurons was tested (GT1-7 cells) (I, II and IV). In addition, human lung (HL), 
liver (HepG2) and epithelial (Caco2) cells were exposed to the active compounds. The most 
active compounds in publication I, II and IV did not show any cytotoxic effect in the cell 
lines tested, thus showing that these compounds are not only potent selective BChE 
inhibitors but also that they do not affect the cell viability up to concentrations of 50 µM (I) 
or 100 µM (II and IV), which is well above the potency values. No cytotoxicity was tested in 
publication III as the most active compound, chelerythrine, had already been shown to be 
well-tolerated (Chmura et al., 2000; Niu et al., 2011). These compounds may still have 
unwanted effects, for example chelerythrine is a known protein kinase inhibitor and inhibits 
e.g. myotonic dystrophy kinase-related Cdc42-binding kinase (Tan et al., 2011) and protein 
kinase C (Chmura et al., 2000). Also as BChE is abundant in peripheral tissue (Liston et al., 
2004) it is likely that these compounds could result in adverse effects in the periphery. 
However, this is difficult to say at this point as this project is a part of the early drug 
discovery process. 
 
To give a better understanding of the interaction between the most active compounds with 
the cholinesterases and their selectivity towards BChE, molecular docking studies were 
performed (II and IV). In publication II the selectivity of the most active compound (3f) 
towards huBChE was shown to be due to differences in the binding mode of the compound 
to the enzymes. While in huBChE the compound interacted with the residues of the catalytic 
triad (Ser-198 and His-438), it did not do so in huAChE. In publication IV, on the other 
hand, the most active compound (15) was not able to enter the active site gorge of huAChE 
thus explaining its high selectivity towards huBChE. Although the structures of BChE and 
AChE are very similar and dual inhibitors are most frequently found (Musiał et al., 2007), 
the structural differences between the active site gorges (Ngamelue et al., 2007; Dvir et al., 
2010) still offer an opportunity to develop selective BChE inhibitors. 
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It is thought that molecules with similar structural properties should possess similar 
biological activities. Indeed, there is a higher probability of finding biologically active 
compounds among a compound collection with similar structures to already known bioactive 
compounds, but this is not a rule (Martin et al., 2002). Another approach is to not focus 
solely on the structure but to focus more on the physico-chemical properties required of a 
compound that possesses a certain kind of biological activity. This way the probability of 
finding novel compounds with a desired activity is higher. In chemical space, the amount of 
possible molecules is vast and there is therefore a requirement to try and reduce this to an 
area which is considered to be the biologically relevant chemical space (Larsson et al., 2007). 
During this thesis project, we have tried to identify an area that would encompass 
compounds with BChE inhibitory activity. The chemical space that the libraries occupy is 
interesting as one can clearly see the features that have been described for natural and 
synthetic libraries in the past (Figure 14). Natural products are known to be more rigid due 
to their lower amount of rotatable bonds compared to synthetic compounds as well as having 
less aromatic rings (Feher and Schmidt, 2002; Ertl and Schuffenhauer, 2008). ChemGPS-NP 
can be used to identify an area of chemical space where most of the active compounds reside 
(Rosén et al., 2009). In our case, the active compounds span a narrower space, defining a 
chemical space relevant for the types of cholinesterase inhibitors found in this project 
(Figure 15). Of course, as with the Lipinski’s rule of five (Lipinski et al., 1997), there are 
exceptions to this and there are several compounds that do not reside in the area of chemical 
space where our active compounds reside, as we noticed in publication II. However, in 
general, this type of analysis would facilitate future screening as a large part of the library 
can, similarly to using the Lipinski’s rule of five, be left unscreened based on their physico-
chemical properties, as their profile does not fit with the requirements of this type of 
inhibition. 
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6 CONCLUSIONS 
Due to the complexity of AD it is challenging to find one drug to cure this disease, at least 
not until the disease mechanism is better understood. Until that day it is likely that a 
combination of therapies, symptomatic and disease-modifying, is the way forward. 
Cholinesterase inhibitors are thought to be symptomatic treatment, but evidence is pointing 
to the fact that they may have an impact on the progression of the disease as well. The 
existence of BChE has been known for a long time, but its function is still somewhat of a 
mystery. It could be that the task of BChE is to function as a bioscavenger, but BChE could 
also prove to play a more vital role in human health and disease. 
 
During this thesis project, a total of nine chemical classes have been found to inhibit BChE 
(diarylimidazole, benzanilide, thienothiazine, quinazoline, indole, steroid alkaloid, 
isoquinoline, compounds with polycyclic ring system, cinchona alkaloid) and some also 
inhibit AChE (dual inhibitors: quinazoline and isoquinoline) and/or Aβ aggregation 
(bifunctional: diarylimidazole and isoquinoline). They offer structures that can be further 
optimized and importantly, these compounds do not show signs of cytotoxicity up to 50 µM 
in the cell lines tested, suggesting a level of safety when using these scaffolds. The 
compounds found in this study may serve as scaffolds for future development of drug 
candidates in AD or be used as molecular probes in the search for the function of BChE. 
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